Latozinemab (also known as AL-001) is an investigational, human monoclonal antibody designed to target progranulin (PGRN), a key regulatory glycoprotein. It functions as a progranulin elevator by binding to and inhibiting the sortilin-1 (SORT1) receptor, which is responsible for the cellular uptake and lysosomal degradation of progranulin. By blocking this clearance pathway, Latozinemab aims to increase levels of functional progranulin in the brain and peripheral tissues. It is currently in clinical development for the treatment of frontotemporal dementia with progranulin gene mutations (FTD-GRN), a condition characterized by haploinsufficiency and abnormally low progranulin levels.